LSN at The MedTech Conference

27 Oct

By Alexander Vassallo, Manager of Business Development West Coast (US), Entrepreneurial Education Lead, LSN

Life Science Nation (LSN) attended The MedTech Conference at the Boston Convention & Exhibition Center this week alongside some of the industry’s most innovative technology assets and professional development services. Located at Booth #910 and led by Dennis Ford, Founder and CEO of LSN, this was an exciting opportunity to connect with global players in the medtech industry and begin to build lasting relationships for years to come.

Photo

Featuring an array of well-delivered pitches by fundraising executives and interesting panels covering important industry topics, The MedTech Conference powered by AdvaMed provided ample opportunity for networking and establishing the dialogue with key players in the global device sector. Representatives from over 30 countries attended the conference and it was an excellent opportunity for LSN to connect with international groups looking to propagate the growth of their regions’ medical device sectors.

A highlight was connecting with MTPConnect, an Australian-based biotechnology and medical device growth center, which served to further LSN’s relationship with the Australian life sciences community – a relationship that was cemented earlier this year with the engagement of twelve medtech startups from Brisbane Economic Development Agency (BEDA) in LSN’s education curriculum and RESI JPM San Francisco, January 10-12, 2023.

As we approach 2023, maintaining established industry relationships and building new ones through leading partnering events like The MedTech Conference and RESI are essential to continue the growth propagation of the life sciences sector. The opportunity at the Boston Convention & Exhibition Center this week was certainly a rewarding one for all involved. To learn more about RESI and take advantage of exclusive bundles, visit our website and we hope to see you virtually at Digital RESI, November 15-16 and via our hybrid format at RESI JPM San Francisco, January 10-12!

RESI-Nov-2022-500-H-with-border

RESI-SF-2023-Banner

Hot Investor Mandate: Investment Firm and Incubator With US HQ Invests $2-10M in Early & Late-Stage Financings, Most Interested in Therapeutics and Medical Devices

27 Oct

An investment firm and incubator that was established in 2020 and is headquartered in USA has about USD 50 million in assets under management. The firm prefers to participate in early-stage and seed (pre-Series A) financing as well as later-stage and pre-IPO (post-Series B and C) financing while avoiding the middle-stages. The firm manages an evergreen fund with between USD 10 million and USD 20 million of available capital per year. The firm typically makes around 3 or 4 investments per year with typical initial allocation size between USD 2 million and USD 10 million for early-stage companies and around USD 10 million for later-stage companies. The firm utilizes various capital structures as determined on a case- by-case basis and has experience with equity investments and convertible loans. The firm primarily invests in companies based in the United States and China but is open to considering all global opportunities as well.

The firm is primarily interested in investing in companies in the biotechnology therapeutics and medical technology sectors. The firm will consider all modalities across these sectors but has expertise in molecule development and prefers to avoid medical devices. The firm has no experience in digital health but will consider investments in the diagnostics sector but prefers to focus on genomics and biomarker diagnostics. The firm will invest in therapeutics that are pre-clinical or in Phase I to Phase III of clinical trials as well as medical technology and diagnostics that are in development or clinical. The firm is disease agnostic and will consider companies across all indications but has experience investing in cancer and autoimmune related technologies.

The firm prefers to work with experienced management teams are dedicated to their technology and their company. The firm is an active investor and will take a board seat on a case-by-case basis depending on investment size. Plaisance Capital Management will act as both a lead and co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Canada-Based VC Seeks Global Opportunities in the Field of Precision Medicine, Investing in Therapeutics, Devices, AI/Digital Health, and More

27 Oct

A venture capital firm with offices in Canada was founded by a leading venture capital firm’s former healthcare investment team, who has a successful track record of identifying, building, and growing life science companies. The firm’s newest fund will invest around 80% in Canada-based life science companies and 20% in USA/global companies. The firm will generally participate in Series A financing rounds and beyond, including crossover and IPO; average check sizes will be around $5-10M CAD, with a total of $15-20M CAD will be reserved for follow-on investments. In addition, the firm is also dedicated to company incubation and creation for which the firm will work with earlier stage companies and deploy smaller amounts of capital (around $1M CAD).

The firm has a general theme of investing in precision medicine – technologies that can enhance the quality and accuracy of diagnoses, enable more precise and personalized treatments, targeted therapies such as cell & gene therapy, technologies that leverage AI to accelerate therapeutic development, etc. In terms of sector, the firm seeks to invest 50-60% in therapeutics, 20-30% in medical devices, and 10-15% in AI/digital health/diagnostics. For medical devices, the firm prefers later stage opportunities that are close to commercialization. The firm does not focus on any particular indication area.

The firm does not have specific company or management team requirements. While the firm likes to see management teams with a successful track record and wide range of experiences, this is not required and the firm is open to working on inexperienced management teams. The firm is capable of leading or co-leading investment rounds, and is also open to co-investing with likeminded investors. The firm is very hands-on and leverages their network to actively support the growth of their portfolio companies and provide needed resources.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Investment Firm Allocates Up to $10M in Series A & B Financings of Medical Devices, Diagnostics, and Digital Health Companies Across the Globe

27 Oct

A venture capital firm founded in 2020 and based in the US is seeking opportunities in the medical devices, diagnostics, and digital health sectors of life sciences. The firm is looking to engage in Series A to Series B financing rounds with check sizes between 5 – 10 million USD. The firm prefers to lead the financing rounds but is open to co-investing. The firm will consider opportunities globally.

The firm is interested in early-stage opportunities in medical devices, diagnostics, and digital health sectors but does not invest in therapeutics. The firm is overall opportunistic and will consider various subsectors and indications. For digital health, the firm prefers b-to-b over b-to-c products. The firm will invest in all early-stage companies including pre and post commercial enterprises.

The firm seeks to work with management teams that have prior entrepreneurial experience. The firm prefers to lead financing rounds and will most likely take a board seat when leading. The firm considers themselves an active investor and will work closely with companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Healthcare-Focused VC Invests in Early-Stage Life Science Companies in All Sectors, With Strong Interest in Platform Technologies

27 Oct

A USA-based investment firm was founded with a focus on early stage healthcare companies. The firm currently has 34 companies in their portfolio with 4 exits. The firm invests in all 4 life science sectors and the typical check size ranges from $100K – 500K and typically helps fill out existing rounds once there is a lead investor in-place. The firm generally seeks to make investments into emerging life science companies in Pre-Seed, Seed and Series A stages. The firm is US focused in terms of geographic preference, but will occasionally look outside of the US.

The firm invests across all life science verticals and is open to all 4 sectors. The firm looks for novel technologies in biotech, medtech, digital health therapeutics, and diagnostics. In terms of biotech companies, the firm focuses on biotechnology platforms rather than single asset biotech companies. The firm is agnostic to both subsector and indication and is open to both pre-clinical therapeutic companies as well as all three stages of medical devices.

The firm is open to all types of management teams, with a goal to democratize who gets funding in the life science space. The firm is looking for diversity in the management team to combine ideas and skill set. The firm prefers to co-invest rather than lead.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Sharpen Your Sword at Digital RESI November and Slay the Dragons at RESI JPM San Francisco

20 Oct

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

Successful fundraising campaigns begin in 2022. Planning your 2023 capital investor and licensing roadshow needs to start with a full-on run at Digital RESI November. Life Science Nation (LSN) is offering a bundle package for Digital RESI November and RESI JPM San Francisco to get your best foot forward for funding in 2023. Digital RESI November is a two-day dedicated virtual partnering event featuring 250 investors and strategic partners, most of whom also showing up for RESI San JPM Francisco for in-person meetings. This affords startups the opportunity to sort their partner target list and set up for a fruitful JPM week, kicking off your global 2023 partnering. The combination of virtual and in-person meetings is compelling (one thing we got out of Covid) as you can save time and money on travel, while still securing the key meetings with strategic players that are a fit for your exact stage of development and product set.

LSN knows hybrid events work, as we have procured some interesting metrics at our RESI Boston event in September.  We saw 600 attendees show up to RESI Boston with an additional 300 for the virtual component. These numbers were evenly split by fundraising CEOs and scientist-entrepreneurs and capital investors and licensing partners. LSN also found that 250 of the sell-side attendees got a majority of the 2,000 meetings by making multiple requests and leveraging an appropriate follow-up process to the buy-side attendees. The numbers speak for themselves with an average of 8-12 meetings, with many having over 20 meetings. Securing a strategic partnership is a numbers game and sticking with a proven process to identify the right targets through our match-based partnering system and then going after meetings with these matched partners works.

LSN hosts five Redefining Early Stage Investments (RESI) events each year around the globe. Strategic partnering doesn’t work by attending one or two events. You need to generate some mojo and get yourself in front of the global players that are a fit. Virtually or in-person, it all starts with the initial dialogue that will develop into a relationship over multiple meetings, and eventually, a deal.

Check out the Digital RESI November and RESI San JPM Francisco bundle and and kick off your 2023 strategic partner roadshow in a few short weeks! RESI San JPM Francisco is one of the most compelling and dynamic meetings of the year with 1,200 attendees, and is usually sold out a week or so beforehand, so investing in the package now is a no-brainer!

Register-now-button-new

RESI-Nov-2022-500-H-with-border

RESI-SF-2023-Banner

RESI JPM San Francisco Pitch Application Open

20 Oct

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

claire

The Redefining Early Stage Investments (RESI) San Francisco 2023 Innovator’s Pitch Challenge (IPC) application is now open!

RESI Boston saw nearly 60 early-stage companies across therapeutics, medical devices, diagnostics, digital health pitch in front of judging panels of investors and industry experts, accompanied by a full audience with standing room only. Each finalist company also prepares a posterboard to be showcased in the exhibit hall and competes for “RESI Cash” which attendees use to “invest” in their favorite presenters for the final prizes.

2022_0921_RESIBoston_007s2022_0921_RESIBoston_001s

RESI JPM San Francisco is the biggest conference of the year, attracting nearly 1,200 attendees, and we are thrilled to return to an in-person format for the first time in three years. Participating in the IPC is a great way to boost your visibility and receive valuable feedback from investors and strategic partners. Do not miss out on the opportunity to pitch at one of the largest RESIs of the year, during the life science industry’s busiest week!

The deadline to apply is Wednesday, November 30, but we expect slots to fill very quickly and highly encourage early application submissions!

RESI-Nov-2022-500-H-with-border

RESI-SF-2023-Banner

← Older Entries
Newer Entries →